Payment overview · 2025
General Payments
$1,317.84
74 reported records · 16 companies
Healthcare provider profile · identity verified
Clay Eugene Stalcup, MD
Allopathic & Osteopathic Physicians|Family Medicine · SEYMOUR, TN · NPI 1750389979
Verified facts
What the public records show
CMS Open Payments records show Clay Eugene Stalcup, MD received $1,317.84 in general payments during 2025 across 74 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $209.79 | 15.9% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $201.75 | 15.3% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $192.81 | 14.6% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.48 | 11.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $96.01 | 7.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.32 | 6.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.56 | 5.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.61 | 3.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.26 | 3.6% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $42.56 | 3.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.89 | 3.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.21 | 2.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.66 | 2.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.84 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.99 | 1.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.10 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,317.84 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $209.79 | 16 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $192.81 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.15 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $113.06 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.07 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $82.32 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $82.32 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $82.32 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.95 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.63 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.60 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $50.61 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $47.26 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $39.89 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.21 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.21 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 71 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 100 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 775 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 530 | 136 |
| Lisinopril | Lisinopril | 427 | 111 |
| Omeprazole | Omeprazole | 355 | 93 |
| Gabapentin | Gabapentin | 332 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 307 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 69 |
| Metformin Hcl | Metformin Hcl | 262 | 74 |
| Fluticasone Propionate | Fluticasone Propionate | 255 | 99 |
| Losartan Potassium | Losartan Potassium | 223 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 51 |
| Montelukast Sodium | Montelukast Sodium | 201 | 50 |
| Simvastatin | Simvastatin | 184 | 49 |
| Glimepiride | Glimepiride | 177 | 48 |
| Furosemide | Furosemide | 154 | 45 |
| Buprenorphine Hcl | Buprenorphine Hcl | 144 | suppressed |
| Alprazolam | Alprazolam | 143 | 16 |
| Eliquis | Apixaban | 138 | 30 |
| Carvedilol | Carvedilol | 129 | 32 |
| Meloxicam | Meloxicam | 129 | 40 |
| Potassium Chloride | Potassium Chloride | 127 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 17 |
| Ozempic | Semaglutide | 117 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 30 |
| Famotidine | Famotidine | 102 | 36 |
| Baclofen | Baclofen | 100 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 18 |
| Ezetimibe | Ezetimibe | 98 | 28 |
| Trazodone Hcl | Trazodone Hcl | 97 | 22 |
| Mirtazapine | Mirtazapine | 94 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 27 |
| Metformin Hcl Er | Metformin Hcl | 88 | 20 |
| Finasteride | Finasteride | 85 | 23 |
| Clonazepam | Clonazepam | 81 | 18 |
| Azelastine Hcl | Azelastine Hcl | 71 | 41 |
| Farxiga | Dapagliflozin Propanediol | 71 | 21 |
| Lorazepam | Lorazepam | 69 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 54 |
| Tramadol Hcl | Tramadol Hcl | 66 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 12 |
| Sertraline Hcl | Sertraline Hcl | 62 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 15 |
| Benazepril Hcl | Benazepril Hcl | 59 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 14 |
| Methylprednisolone | Methylprednisolone | 58 | 46 |
| Enalapril Maleate | Enalapril Maleate | 57 | 15 |
| Jardiance | Empagliflozin | 55 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 14 |
| Propranolol Hcl | Propranolol Hcl | 53 | 11 |
| Warfarin Sodium | Warfarin Sodium | 53 | 11 |
| Diazepam | Diazepam | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 13 |
| Linzess | Linaclotide | 49 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Celecoxib | Celecoxib | 45 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 12 |
| Cefdinir | Cefdinir | 43 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 37 |
| Buspirone Hcl | Buspirone Hcl | 41 | 14 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 39 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Ramipril | Ramipril | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Nystatin | Nystatin | 23 | 17 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Valsartan | Valsartan | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 12 |
| Spironolactone | Spironolactone | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Topamax | Topiramate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,317.84 · 74 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, FARXIGA, GVOKE HYPOPEN, Kerendia, LEQVIO, Leqembi, MAVYRET, MOUNJARO, NEXLETOL, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error